Erratum: Erythropoietin dosing in children with chronic kidney disease: Based on body size or on hemoglobin deficit? (Pediatric Nephrology (2009) 10.1007/s00467-008-0955-2);Erythropoietin dosing in children with chronic kidney disease: Based on body size or on hemoglobin deficit?

Pediatric Nephrology

Volumn 24, Issue 3, 2009, Pages 435-437

  Port, Ruediger E ^a   Mehls, Otto ^b  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CKD adults; CKD children; EPO resistance; Prediction model; Principle of EPO dosing; Renal anemia

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; BLOOD VOLUME; BODY GROWTH; BODY SIZE; CHILD; CHILD CARE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; EDITORIAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

EID: 59849094425     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1219-5     Document Type: Erratum

References (23)

1. Bamgbola OF, Kaskel FJ, Coco M (2008) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol doi: 10.1007/s00467-008-0954-3
2. Eschbach JW, Adamson JW (1989) Guidelines for recombinant human erythropoietin therapy. Am J kidney Dis 14(2 Suppl 1):2-8
3. Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266-273
4. Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H (1994) A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol 8:338-342
5. Van Damme-Lombaerts R, Herman J (1999) Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13:148-152
6. Gagnadoux MF, Loirat C, Berthélémé JP, Maisin A, Kamoun A, Dabout D, Poisson D, Broyer M (1994) Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial. Nephrologie 15:207-211
7. Al-Hermi BE, Al-Saran K, Secker D, Geary DF (1999) Hemodialysis for end-stage renal disease in children weighing less than 10 kg. Pediatr Nephrol 13:401-403
8. Seeherunvong W, Rubio L, Abitbol CL, Montané B, Strauss J, Diaz R, Zilleruelo G (2001) Identification of poor responders to erythropoietin among children undergoing hemodialysis. J Pediatr 138:710-714
9. Besarab A (2006) Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 69:S13-S18
10. Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: No justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57-70
11. Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76-89
12. Brockmöller J, Köchling J, Weber W, Looby M, Roots I, Neumayer HH (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 34:499-508
13. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266-281
14. Hathcock JN, Shao A, Vieth R, Heaney R (2007) Risk assessment for vitamin D. Am J Clin Nutr 85:6-18
15. Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49:814-823
16. Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ (1999) Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 56:306-317
17. Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Pediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151-159
18. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, Neeraj G, Veng-Pedersen P, Christensen RD (2005) Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol 25:725-730
19. Maier RF, Obladen M, Müller-Hansen I, Kattner E, Merz U, Arlettaz R, Groneck P, Hammer H, Kössel H, Verellen G, Stock GJ, Lacaze-Masmonteil T, Claris O, Wagner M, Matis J, Gilberg F, European Multicenter Erythropoietin Beta Study Group (2002) Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 141:8-15
20. Bührer C, Obladen M, Maier R, Müller C (2003) Urinary losses of recombinant erythropoietin in preterm infants. J Pediatr 142:452-453
21. Noguchi CT, Asavaritikrai P, Teng R, Jia Y (2007) Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64:159-171
22. Fliser D, Bahlmann FH, Haller H (2006) EPO: Renoprotection beyond anemia correction. Pediatr Nephrol 21:1785-1789
23. Vihervuori E, Virtanen M, Koistinen H, Koistinen R, Seppälä M, Siimes MA (1996) Hemoglobin level is linked to growth hormone-dependent proteins in short children. Blood 87:2075-2081